Viktor Grünwald

40PUBLICATIONS
192CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (40)

|Jul 28, 2026
Impact of COPD on Outcomes After Pulmonary Metastasectomy: A Propensity-Score Matched Analysis.

|Jul 18, 2026
OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117).

|Jul 15, 2026
Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma After Prior Therapy: Final Results from the Non-Interventional NORA Study.

|May 19, 2026
Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group.

|Dec 30, 2025
First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex.

Viktor Grünwald, Karen Rußwurm, Ralf Eckert

|Dec 04, 2025
[The WHO Classification of Renal Cell Tumours: Implications for Personalised Treatment Decisions and Accurate Detection of Hereditary Renal Cell Carcinomas].

Marieta Ioana Toma, Roman-Ulrich Müller, Viktor Grünwald

Pageof 7

Frequent Collaborators

4 joint publications

Martin Schuler

4 joint publications

Sebastian Bauer

3 joint publications

Michael Hölzel

3 joint publications

Martin Bögemann